Evidence map›Paper›PMID 35403370›Full record

ArticleACR open rheumatology2022

Time-Varying Association of Rheumatoid Arthritis Disease Activity to Subsequent Cardiovascular Risk.

Kazuki Yoshida, Leslie R Harrold, Nicole Middaugh, Hongshu Guan, Scott Stryker, Elaine Karis, Daniel H Solomon

Open access · goldAbstract read
In one paragraph

Article in ACR open rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. The Effect of TNF-Cardiology research and practice · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Kazuki YoshidaBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.ORCID https://orcid.org/0000-0002-2030-3549
Leslie R HarroldUniversity of Massachusetts Medical School, Worcester, and CorEvitas, LLC, Waltham, Massachusetts.
Nicole MiddaughCorEvitas, Waltham, Massachusetts.
Hongshu GuanBrigham and Women's Hospital, Boston, Massachusetts.
Scott StrykerAmgen Inc., Thousand Oaks, California.
Elaine KarisAmgen Inc., Thousand Oaks, California.
Daniel H SolomonBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Brigham and Women's Hospital · USAmgen (United States) · USBoston Sports & Shoulder Center · USUniversity of Massachusetts Chan Medical School · US

Funding

VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYticsP30AR072577 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Elena Losina · 2017 to 2026
$9.8M
Gout and Cardiovascular Comorbidities: Disentangling the Interplay with Advanced Methods to Address Measurement IssuesK23AR076453 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI YOSHIDA, KAZUKI · 2020 to 2022
$439k
NIAMS NIH HHS K23 AR076453NIAMS NIH HHS P30 AR072577
6 · The paper itself

Abstract

objectiveIt is unknown how the relationship between disease activity in rheumatoid arthritis (RA) and cardiovascular (CV) events may change over time. We examined the potentially time-varying association of RA disease activity to CV events.

methodsWe used the CorEvitas prevalent RA registry. The Clinical Disease Activity Index (CDAI) score category, averaged within each 6-month window since enrollment, was the exposure, and the outcome was major adverse CV events (MACEs). We used marginal structural models to estimate the hazard ratio (HR), comparing each CDAI score category with remission, allowing for differential association over time. We predicted MACE-free survival under several CDAI score scenarios.

resultsWe found 44,816 eligible patients (77% female; mean age 58 years) with a crude event rate of 5.3/1000 person-years (median follow-up 3.4 years). The strongest association between higher CDAI score and MACEs was observed during the first 6 months of enrollment (HR for CDAI score low 2.29 [95% CI: 1.21-4.36], moderate 2.81 [95% CI: 1.46-5.43], and high 2.99 [95% CI: 1.48-6.02]). These estimates gradually diminished; by year 5, the HRs were 1.00 (95% CI: 0.49-2.05) for low, 1.18 (95% CI: 0.51-2.71) for moderate, and 1.04 (95% CI: 0.45-2.40) for high CDAI score. Predicted MACE-free survival suggested a potential decrease in MACEs with a hypothetical earlier transition to remission.

conclusionThe association of higher disease activity with CV events may be stronger earlier in the disease course of RA. Interventional studies may be warranted to precisely determine the effect of disease activity suppression on CV events in RA.

Identifiers

PMID35403370
PMCPMC9274374
OpenAlexW4223415262

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.